Prevalence of Malignant Hyperthermia and Relationship with Anesthetics in Japan

Sumitani, Masahiko; Uchida, Kanji; Yasunaga, Hideo; Horiguchi, Hiromasa; Kusakabe, Yoshiomi; Matsuda, Shinya; Yamada, Yosuke

doi:10.1097/aln.0b013e318200197d

Cited by 88 publications

(68 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Japanese study conducted in the period 2006-2008 shows a prevalence of 13.7 cases per million. (3) In New York, a study describes 73 cases diagnosed from [2001][2002][2003][2004][2005]. (4) In Brazil, there are no current data on the incidence; however, it is estimated that general anesthesia is performed approximately fi ve million times annually, and therefore this number is consistent with the annual incidence of 500 to 1,000 cases of MH in São Paulo alone.…”

Section: Introductionmentioning

confidence: 53%

Knowledge of nursing professionals of a surgical center regarding malignant hyperthermia

Sousa

Cunha

2014

Rev. Gaúcha Enferm.

View full text Add to dashboard Cite

The objective of this study was to assess the knowledge of the nursing professionals in a surgical center about malignant hyperthermia. This is a descriptive exploratory study on malignant hyperthermia conducted with mid- and high-level nursing professionals in the surgical center of an institution located in the city of São Paulo, where the research was conducted between August and September 2013. Analysis of the data was descriptive and the average of the correct answers was compared using Student's t-test. Among the 96 participants, the two items in which at least 70% of the team showed knowledge were: the definition of malignant hyperthermia and the professionals involved in the health care provided. With respect to all test items, 70% of nurses answered 50% correctly. The same percentage of mid-level professionals answered only 20% correctly. There was no statistically significant difference between the professional categories. This study revealed insufficient knowledge on the part of the nursing team about malignant hyperthermia.

show abstract

Section: Introductionmentioning

confidence: 53%

Knowledge of nursing professionals of a surgical center regarding malignant hyperthermia

Sousa

Cunha

2014

Rev. Gaúcha Enferm.

View full text Add to dashboard Cite

show abstract

“…[4][5][6] El SHM puede presentarse en forma rápida, en la inducción anestésica, relacionado con el uso de succinilcolina y asociado a rigidez muscular y mayor repercusión orgánica, o en forma tardía, en la anestesia o posteriormente, asociado al uso de agentes inhalatorios halogenados (sevoflurano, isoflurano, halotano y enflurano), y puede ocurrir con o sin rigidez y variabilidad en la magnitud del compromiso orgánico. También pueden existir formas de presentación abortivas o menores.…”

Section: Introductionunclassified

Síndrome de hipertermia maligna: a propósito de un caso clínico

Taffarel

Koffman²,

Zifferman

et al. 2015

Arch Argent Pediat

View full text Add to dashboard Cite

Arch Argent Pediatr 2015;113(2):e113-e116 / e113Presentación de casos clínicos RESUMEN El síndrome de hipertermia maligna es una miopatía familiar de naturaleza farmacogenética, que se presenta como un síndrome hipercatabólico del músculo esquelético ligado a la anestesia. La incidencia en pediatría es de 1 cada 10 000 cirugías. Puede ser de instalación rápida, asociado a succinilcolina, o tardía, relacionado con agentes inhalatorios. El cuadro ocurre con taquicardia, hipertermia, hipercapnia, acidosis, rigidez muscular, hiperpotasemia, falla renal y arritmia. La mortalidad sin tratamiento específico es del 80% y desciende al 7% con el uso de dantroleno sódico. Reportamos el caso de un paciente de 8 años que se internó para cirugía de fimosis. Por presentar taquicardia, hipercapnia y rigidez muscular, se inició tratamiento con dantroleno sódico en quirófano, el cual se mantuvo durante 72 h. Evolucionó las primeras 12 h con bajo gasto cardíaco, con máximo valor de creatina fosfoquinasa de 155 147 U/L. Permaneció con asistencia mecánica respiratoria por 48 h. Se otorgó alta al sexto día, sin secuelas. Palabras clave: hipertermia maligna, dantroleno sódico, creatina fosfoquinasa. ABSTRACTMalignant hyperthermia syndrome is a family myopathy of pharmacogenetic nature, which appears as a skeletal muscle hypercatabolic syndrome linked to anesthesia. The incidence in pediatrics is 1 event per 10 000 surgeries. The clinical picture may have a rapid onset associated with succinylcholine, or a late onset related to inhalation agents. The clinical picture includes tachycardia, hyperthermia, hypercapnia, acidosis, muscle rigidity, hyperkalemia, renal failure and arrhythmia. Mortality without specific treatment is of 80% and drops to 7% with the use of dantrolene sodium. We report an 8-year-old patient admitted for phimosis surgery; having tachycardia, hypercapnia and muscle rigidity, he started treatment with dantrolene sodium in the operating room, which was maintained for 72 hours. He evolved the first 12 hours with low cardiac output and creatine phosphokinase maximum of 155 147 U/L. He remained with mechanical ventilation for 48 hours. Discharge was given on the sixth day without sequelae.

show abstract

“…Malignant hyperthermia is more common in male patients 25 . The incidence and prevalence varies from country to country, based on differences in gene pools [26][27][28][29][30] .…”

Section: Incidence and Prevalencementioning

confidence: 99%